Get Live Data

Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. TILS.L Share Price
  4. TILS.L Share Regulatory News
  5. TLSA to Present at the Q3 Virtual Investor Summit

Pin to quick picksTILS.L Regulatory News (TILS)

TILS.L Information
  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TLSA to Present at the Q3 Virtual Investor Summit

16 Aug 2021 18:11

RNS Number : 8136I
Tiziana Life Sciences PLC
16 August 2021
 

Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit

NEW YORK & LONDON, August 16, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces today that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit.

 Event

 Q3 Investor Summit

 Date

 August 17-18th, 2021

 Presentation

 August 18th at 3.30pm ET

 Location

 https://zoom.us/webinar/register/WN_Az9VTw1QRr6aESxsPWSloQ

 

About Tiziana Life Sciences plc

Tiziana Life Sciences plc (NASDAQ: TLSA) (LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.

For further information:

Tiziana Life Sciences plcKunwar Shailubhai02074952379info@tizianalifesciences.com

About the Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q3 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.

To request complimentary investor registration: please click here: Complimentary Investor Registration

Contact:

Sasha Murray at sasha@investorsummitgroup.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXPKFENFEFA
3456789101112
Date   Source Headline
2nd Mar 201812:09 pmRNSStatement re broker
22nd Jan 20187:00 amRNSPlacing
16th Jan 20187:00 amRNSPlacing
15th Dec 20177:00 amRNSPlacing and Issue of Equity
8th Dec 20177:00 amRNSMilciclib Phase 2a Trial Update
27th Nov 20177:00 amRNSPlacing
23rd Nov 20177:00 amRNSPhase II Clinical Trial Update
20th Nov 20177:00 amRNSSubscription
29th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
6th Sep 20177:00 amRNSA Proprietary Oral Formulation of Foralumab
31st Aug 201711:07 amRNSGrant of options - Director's dealing
16th Aug 20177:00 amRNSConversion of outstanding loan notes
28th Jul 20177:00 amRNSPublication of Research Article on Foralumab
19th Jul 20177:00 amRNSInitiation of a Phase IIa Clinical Trial
12th Jul 20177:00 amRNSProposed changes to CLNs and Warrant Terms
29th Jun 201711:21 amRNSResult of AGM
12th Jun 20177:00 amRNSAppointment of Dr Kunwar Shailubhai as CEO
8th Jun 201710:02 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
8th Jun 20178:14 amRNSBcl-3 pre-clinical update and Director's dealing
1st Jun 20177:00 amRNS2016 Annual Report and Accounts and notice of AGM
23rd May 20177:00 amRNSFinancial Results for Year Ended 31 December 2016
24th Apr 20177:14 amRNSAnnounces Approval of a Phase II Clinical Trial
21st Apr 20177:00 amRNSAnnounces Publication of Milciclib Clinical Trial
24th Mar 20177:00 amRNSExercise of Warrants & Issue of Equity
14th Mar 20177:00 amRNSArun Sanyal appointed to Scientific Advisory Board
16th Jan 20177:00 amRNSWarrant Expiry - Reminder
3rd Jan 20177:00 amRNSTiziana Life Sciences in-licenses NI-1201
16th Nov 20167:00 amRNSNew Data with Foralumab
7th Nov 201612:29 pmRNSGrant of options
29th Sep 20167:00 amRNSHalf-year Report
15th Sep 20167:00 amRNSConfirmation of Capital Reduction
18th Aug 20167:00 amRNSChange of Registered Office
18th Jul 20167:00 amRNSTiziana acquires a unique bio-repository
30th Jun 201612:47 pmRNSResult of AGM
29th Jun 20167:00 amRNSIssue of Equity
10th Jun 201610:18 amRNSGrant of options and realisation bonus
7th Jun 20167:00 amRNSFinal Results
1st Jun 20167:00 amRNSPartnership with Cardiff Researchers Wins Award
19th May 20167:00 amRNSJournal review of anti - CD3 monoclonal antibodies
4th May 20167:00 amRNSAppointment of Dr. Robert Evans
28th Apr 20167:00 amRNSExercise of Warrants & Issue of Equity
4th Apr 20167:00 amRNSChief Financial Officer Appointed
15th Mar 20167:00 amRNSCo-Founder and NED Prof Chris McGuigan Passes Away
16th Feb 20164:40 pmRNSSecond Price Monitoring Extn
16th Feb 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20167:00 amRNSFund raising
11th Jan 20167:00 amRNSDevelopment plans for foralumab & SAB appointments
8th Jan 20167:00 amRNSUpdate on Tiziana's Bcl-3 inhibitor
9th Dec 20158:00 amRNSAppoints James F. Tripp as Chief Operating Officer
8th Dec 20157:00 amRNSFund raising
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.